Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia
· Delayed Price · Currency is MYR 1.250
-0.010 (-0.79%)
At close: Dec 5, 2025
Duopharma Biotech Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 900.68 | 813.7 | 704.73 | 696.72 | 639.18 | 569.9 | Upgrade
|
| Revenue Growth (YoY) | 14.37% | 15.46% | 1.15% | 9.00% | 12.16% | -1.14% | Upgrade
|
| Cost of Revenue | 558.05 | 512.16 | 436.4 | 416.9 | 385.19 | 336.7 | Upgrade
|
| Gross Profit | 342.62 | 301.54 | 268.33 | 279.82 | 253.98 | 233.2 | Upgrade
|
| Selling, General & Admin | 217.4 | 202.02 | 182.72 | 186.59 | 165.78 | 150.81 | Upgrade
|
| Other Operating Expenses | 0.58 | 0.7 | 2.8 | 0.81 | -0.67 | 1.35 | Upgrade
|
| Operating Expenses | 216.54 | 201.28 | 189.61 | 186.91 | 165.22 | 151.35 | Upgrade
|
| Operating Income | 126.08 | 100.26 | 78.71 | 92.91 | 88.77 | 81.86 | Upgrade
|
| Interest Expense | -23.99 | -25.77 | -17.68 | -9.1 | -6.44 | -6.53 | Upgrade
|
| Interest & Investment Income | 5.78 | 5.97 | 2.75 | 1.52 | 1.2 | 1.51 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.82 | -0.82 | -0.52 | -0.48 | -0.53 | -0.68 | Upgrade
|
| EBT Excluding Unusual Items | 107.05 | 79.63 | 63.27 | 84.85 | 82.99 | 76.16 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.39 | 0.39 | - | - | -0.01 | - | Upgrade
|
| Pretax Income | 107.45 | 80.02 | 63.27 | 84.85 | 82.98 | 76.16 | Upgrade
|
| Income Tax Expense | 23.95 | 17.38 | 10.62 | 14.74 | 17.3 | 17.55 | Upgrade
|
| Net Income | 83.5 | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade
|
| Net Income to Common | 83.5 | 62.65 | 52.65 | 70.11 | 65.68 | 58.61 | Upgrade
|
| Net Income Growth | 48.93% | 19.00% | -24.91% | 6.74% | 12.07% | 6.04% | Upgrade
|
| Shares Outstanding (Basic) | 961 | 962 | 959 | 948 | 928 | 928 | Upgrade
|
| Shares Outstanding (Diluted) | 961 | 962 | 959 | 948 | 928 | 928 | Upgrade
|
| Shares Change (YoY) | -0.12% | 0.36% | 1.08% | 2.15% | 0.02% | 3.86% | Upgrade
|
| EPS (Basic) | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 | 0.06 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.07 | 0.05 | 0.07 | 0.07 | 0.06 | Upgrade
|
| EPS Growth | 49.07% | 18.57% | -25.71% | 4.50% | 12.05% | 2.09% | Upgrade
|
| Free Cash Flow | 80.13 | 59.77 | 15.86 | 5.08 | -66.16 | 15.24 | Upgrade
|
| Free Cash Flow Per Share | 0.08 | 0.06 | 0.02 | 0.01 | -0.07 | 0.02 | Upgrade
|
| Dividend Per Share | 0.035 | 0.030 | 0.023 | 0.023 | 0.022 | 0.049 | Upgrade
|
| Dividend Growth | 25.00% | 30.44% | - | 5.75% | -55.43% | 8.44% | Upgrade
|
| Gross Margin | 38.04% | 37.06% | 38.07% | 40.16% | 39.74% | 40.92% | Upgrade
|
| Operating Margin | 14.00% | 12.32% | 11.17% | 13.33% | 13.89% | 14.36% | Upgrade
|
| Profit Margin | 9.27% | 7.70% | 7.47% | 10.06% | 10.28% | 10.28% | Upgrade
|
| Free Cash Flow Margin | 8.90% | 7.35% | 2.25% | 0.73% | -10.35% | 2.67% | Upgrade
|
| EBITDA | 163.24 | 137.34 | 114.04 | 122.86 | 114.94 | 105.93 | Upgrade
|
| EBITDA Margin | 18.12% | 16.88% | 16.18% | 17.63% | 17.98% | 18.59% | Upgrade
|
| D&A For EBITDA | 37.16 | 37.08 | 35.32 | 29.95 | 26.18 | 24.08 | Upgrade
|
| EBIT | 126.08 | 100.26 | 78.71 | 92.91 | 88.77 | 81.86 | Upgrade
|
| EBIT Margin | 14.00% | 12.32% | 11.17% | 13.33% | 13.89% | 14.36% | Upgrade
|
| Effective Tax Rate | 22.29% | 21.72% | 16.79% | 17.37% | 20.85% | 23.04% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.